Treatment-resistant lingual Crohn's disease disappears after infliximab

Scandinavian Journal of Gastroenterology

Volumn 40, Issue 10, 2005, Pages 1255-1259

  Brunner, Brigitte ^a   Hirschi, Claudia ^a   Weimann, Rosemarie ^a   Seibold, Frank ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Infliximab; Lingual Crohn's disease; Treatment of resistant Crohn's disease

Indexed keywords

AMYLASE; AZATHIOPRINE; HEXETIDINE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; MONOCLONAL ANTIBODY; SALAZOSULFAPYRIDINE; STEROID; TOPICAL AGENT; TRIACYLGLYCEROL LIPASE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ARTHRALGIA; ARTICLE; CASE REPORT; CLINICAL FEATURE; CROHN DISEASE; DIFFERENTIAL DIAGNOSIS; ENZYME BLOOD LEVEL; HUMAN; MALE; MOUTH ULCER; PRIORITY JOURNAL; TONGUE DISEASE;

ANTIBODIES, MONOCLONAL; CROHN DISEASE; DIAGNOSIS, DIFFERENTIAL; DRUG RESISTANCE; GASTROINTESTINAL AGENTS; HUMANS; MALE; MIDDLE AGED; ORAL ULCER;

EID: 27144484456     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520510023512     Document Type: Article

References (28)

1. Basu MK, Asquith P, Thompson RA, Cooke WT. Oral manifestations of Crohn's disease. Gut 1975;16:249-54.
2. Lisciandrano D, Ranzi T, Carrassi A, Sardella A, Campanini MC, Velio P, et al. Prevalence of oral lesions in inflammatory bowel disease. Am J Gastroenterol 1996;91:7-10.
3. Dupuy A, Cosnes J, Revuz J, Delchier JC, Gendre JP, Cosnes A. Oral Crohn disease: clinical characteristics and long-term follow-up of 9 cases. Arch Dermatol 1999;135:439-42.
4. Plauth M, Jenss H, Meyle J. Oral manifestations of Crohn's disease: an analysis of 79 cases. J Clin Gastroenterol 1991;13:29-37.
5. Halme L, Meurman JH, Laine P, von Smitten K, Syrijanen S, Lindqvist C, et al. Oral findings in patients with active or inactive Crohn's disease. Oral Surg Oral Med Oral Pathol 1993;76:175-81.
6. Hanauer ST, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. and the ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
7. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85.
8. Mahadevan U, Sandborn WJ. Infliximab for the treatment of orofacial Crohn's disease. Inflamm Bowel Dis 2001;7:38-42.
9. Kugathasan S, Miranda A, Nocton J, Drolet BA, Raasch C, Binion DG. Dermatologic manifestations of Crohn disease in children: response to infliximab. J Pediatr Gastroenterol Nutr (JPGN) 2003;37:150-4.
10. Dudeney TP, Todd IP. Crohn's disease of the mouth. Proc R Soc Med 1969;62:1237.
11. Dyer NH, Cook PL, Kemp-Harper RA. Oesophageal stricture associated with Crohn's disease. Gut 1969;10: 549-54.
12. Estrin HM, Hughes RW. Oral manifestations in Crohn's disease: report of a case. Am J Gastroenterol 1985;80:352-4.
13. Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine 1976;55:401-12.
14. Pittock S, Drumm B, Fleming P, McDermott M, Path MRC, Imrie C, et al. The oral cavity in Crohn's disease. J Pediatr 2001;138:767-71.
15. Katz J, Shenkman A, Stavropoulos F, Melzer E. Oral signs and symptoms in relation to disease activity and site of involvement in patients with inflammatory bowel disease. Oral Dis 2003;9:34-40.
16. Ferguson MM, Wray D, Carmichael HA, Russel RI, Lee FD. Coeliac disease associated with recurrent aphthae. Gut 1980;21:223-6.
17. Veloso FT, Saleiro JV. Small-bowel changes in recurrent ulceration of the mouth. Hepatogastroenterology 1987;34: 36-7.
18. Bang D, Hur W, Lee ES, Lee S. Prognosis and clinical relevance of recurrent oral ulceration in Behçet's disease. J Dermatol 1995;22:926-9.
19. Porter SR, Scully C, Pedersen A. Recurrent aphthous stomatitis. Crit Rev Oral Biol Med 1998;9:306-21.
20. Porter S, Flint S, Scully C, Keith O. Recurrent aphthous stomatitis: the efficacy of replacement therapy in patients with underlying haematinic deficiencies. Ann Dent 1992;51: 14-6.
21. Cawson RA, Binnie WH, Barrett AW. Oral disease, clinical and pathological correlations, 3rd ed. London: Mosby; 2001.
22. Li AC, Warnakulasuriya S, Thompson R. Neoplasia of the tongue in a patient with Crohn's disease treated with azathioprine: case report. Eur J Gastroenterol Hepatol 2003;15:185-7.
23. Williams AJ, Wray D, Ferguson A. The clinical entity of orofacial Crohn's disease. Q J Med 1991;79:451-8.
24. Cook MG, Dixon MF. An analysis of the reliability of detection and diagnostic value of various pathological features in Crohn's disease and ulcerative colitis. Gut 1973;14:255-62.
25. Wiesenfeld D, Ferguson MM, Mitchell DN, MacDonald DG, Scully C, Cochrane K, et al. Oro-facial granulomatosis: a clinical and pathological analysis. Q J Med 1985;54:101-13.
26. Kano Y, Shiohara T, Yagita A, Nagashima M. Treatment of recalcitrant cheilitis granulomatosa with metronidazole. J Am Acad Dermatol 1992;27:629-30.
27. Hegarty A, Hodgson T, Porter S. Thalidomide for treatment of recalcitrant oral Crohn's disease and orofacial granulomatosis. Oral Surg Oral Med Oral Pathol 2003;95:576-85.
28. Odeka EB, Miller V. Thalidomide in oral Crohn's disease refractory to conventional medical treatment [Letter; Comment]. J Pediatr Gastroenterol Nutr 1997;25:250-1.